Aug 13
OBOCY · Ottobock SE & Co. KGaA
Market Cap
$4.02B
Shares
319.95M
Volume · Sep 28
200
Avg daily vol (1 sessions)
200
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$12.55
Open$12.55
Day$12.55–12.55
Available close range$12.55–12.55
Avg vol available · 1d200
Short int100 · 0.0% of shares
Short vol50%
Last earningsNov 4, 2027
DataSep 2026–Sep 2026
The closing range uses available history since Sep 28, 2026; less than a full year is stored.
Up next
Feb 16, 2027
Scheduled
· in 14 wks
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
1.8%
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.0%
Latest settlement
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Limited
Momentum
Limited
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Limited
Market backdrop
VIX 18.7 · elevated
Equity put/call 0.72
Technical
price trend
Not enough data for a confident read.
Momentum
relative strength
Not enough data for a confident read.
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.00% of shares out · ▬ 0.0% MoM · 1000.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Squeeze score
13
low risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Not enough data for a confident read.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 13, 2026
Growth rate in this area
· this year
20%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Market signals — smart money & positioning
No clear signal
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.00% of shares out · ▬ 0.0% MoM · 1000.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its available closing range
Price range unavailable — no recent comparable closes.
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OBOCY
this stock
Ottobock SE & Co. KGaA
|
$4.02B | — | — | — | 0.0% |
|
ISRG
Intuitive Surgical Inc
|
$152.49B | -22.3% | +20.5% | 53.3 | 2.0% |
|
BDX
Becton Dickinson & Co
|
$58.76B | — | +8.2% | 95.5 | 3.0% |
|
MDLN
Medline Inc.
|
$52.59B | -4.8% | +11.5% | — | 2.9% |
|
ALC
Alcon Inc
|
$34.51B | -8.9% | +10.5% | — | 3.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OBOCY | — | — | — | — | — |
| SPY | -1.0% | -0.5% | +16.1% | -0.2% | +12.3% |
| vs SPY | — | — | — | — | — |
Capital returns
Latest dividend
$0.2254
/ share · ex May 28, 2026
Paid (TTM)
$0.2254
/ share · 1 payout
Dividend yield (TTM, derived)
— · history filling in
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.